# Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-updated-data-from-beacon-phase-1-2-trial-of-ristoglogene-autogetemcel-risto-cel-highlighting-durable-differentiated-profile-in-sickle-cell-disease-scd-at-american-society-of-hematology-ash-annual-meeting
Ticker: BEAM
Company: Beam Therapeutics
Source: Beam Therapeutics
Published: 2025-12-06 13:00 EST
Original Source URL: https://investors.beamtx.com
## Summary

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to 40%, and Resolution of Anemia Durable for up to 20 Months Patients Required a Median of One Cell Collection Cycle and

## Article Body
Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to 40%, and Resolution of Anemia Durable for up to 20 Months Patients Required a Median of One Cell Collection Cycle and
## Recent Company News
- 2026-05-18 20:00 EST — [Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-presents-recently-reported-topline-clinical-data-for-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-american-thoracic-society-ats-2026-international-conference) — Source: Beam Therapeutics
- 2026-05-13 11:00 EST — [Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-at-2026-rbc-capital-markets-global-healthcare-conference) — Source: Beam Therapeutics
- 2026-05-12 13:30 EST — [Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-biomarker-data-from-phase-1-2-beacon-trial-further-underscoring-risto-cel-s-ability-to-restore-red-blood-cell-health-and-function-in-sickle-cell-disease-at-eha2026) — Source: Beam Therapeutics
- 2026-05-07 11:00 EST — [Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates](https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates) — Source: Beam Therapeutics
- 2026-04-01 21:12 EST — [Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine](https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-publication-of-beacon-phase-1-2-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine) — Source: Beam Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)